Evidence map›Paper›PMID 37124176›Full record

ReviewFrontiers in pediatrics2023

Joint statement for assessing and managing high blood pressure in children and adolescents: Chapter 2. How to manage high blood pressure in children and adolescents.

Elke Wühl, Javier Calpe, Dorota Drożdż, Serap Erdine, Fernando Fernandez-Aranda, Adamos Hadjipanayis, Peter F Hoyer, Augustina Jankauskiene, Susana Jiménez-Murcia, Mieczysław Litwin and 8 more

Abstract readReview
In one paragraph

Review in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Diagnostic evaluation of the hypertensive child.Pediatric nephrology (Berlin, Germany) · 2024
    Article
  6. Association of serum transforming growth factor βEuropean journal of pediatrics · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elke WühlDivision of Pediatric Nephrology, Center for Pediatric and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Javier CalpeAnalog Devices, Inc., Paterna, Spain.
Dorota DrożdżDepartment of Pediatric Nephrology and Hypertension, Pediatric Institute, Jagiellonian University Medical College, Cracow, Poland.
Serap ErdineIstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey.
Fernando Fernandez-ArandaUniversity Hospital of Bellvitge-IDIBELL and Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Adamos HadjipanayisSchool of Medicine, European University Cyprus, Nicosia, Cyprus.
Peter F HoyerKlinik für Kinderheilkunde II, Zentrum für Kinder und Jugendmedizin, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Germany.
Augustina JankauskienePediatric Center, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.
Susana Jiménez-MurciaUniversity Hospital of Bellvitge-IDIBELL and Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Mieczysław LitwinDepartment of Nephrology and Arterial Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
Giuseppe ManciaUniversity of Milano-Bicocca, Milano, Italy.
Artur MazurInstitute of Medical Sciences, Medical College, Rzeszów University, Rzeszow, Poland.
Denes PallDepartment of Medical Clinical Pharmacology and Department of Medicine, University of Debrecen, Debrecen, Hungary.
Tomas SeemanDivision of Pediatric Nephrology, University Children's Hospital, Charles University, Prague, Czech Republic.
Manish D SinhaDepartment of Pediatric Nephrology, Evelina London Children's Hospital, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom.
Giacomo SimonettiInstitute of Pediatrics of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Stella Stabouli1st Department of Pediatrics, Aristotle University of Thessaloniki, Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece.
Empar LurbeCIBER Fisiopatología de Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The joint statement is a synergistic action between HyperChildNET and the European Academy of Pediatrics about the diagnosis and management of hypertension in youth, based on the European Society of Hypertension Guidelines published in 2016 with the aim to improve its implementation. Arterial hypertension is not only the most important risk factor for cardiovascular morbidity and mortality, but also the most important modifiable risk factor. Early hypertension-mediated organ damage may already occur in childhood. The duration of existing hypertension plays an important role in risk assessment, and structural and functional organ changes may still be reversible or postponed with timely treatment. Therefore, appropriate therapy should be initiated in children as soon as the diagnosis of arterial hypertension has been confirmed and the risk factors for hypertension-mediated organ damage have been thoroughly evaluated. Lifestyle measures should be recommended in all hypertensive children and adolescents, including a healthy diet, regular exercise, and weight loss, if appropriate. If lifestyle changes in patients with primary hypertension do not result in normalization of blood pressure within six to twelve months or if secondary or symptomatic hypertension or hypertension-mediated organ damage is already present, pharmacologic therapy is required. Regular follow-up to assess blood pressure control and hypertension-mediated organ damage and to evaluate adherence and side effects of pharmacologic treatment is required. Timely multidisciplinary evaluation is recommended after the first suspicion of hypertension. A grading system of the clinical evidence is included.

Indexed as

adolescentsblood pressurechildrenhypertensionhypertension-mediated organ damagemonitoringtreatment

Identifiers

PMID37124176
PMCPMC10130632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.